Δημοσιεύσεις

ΔΙΕΘΝΗ ΙΑΤΡΙΚΑ ΠΕΡΙΟΔΙΚΑ (peer-reviewed):

1. Nodular Lymphocyte Predominant Hodgkin Lymphoma  with aberrant immunophenotype or variant histopathology: Insights from case series of three patients
G Chander, H Dassanayake, M Kaparou, M Ahmed, B Kishore, E Nikolousis, A Kanellopoulos, Anticancer Research 41 (2021)

2. Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations
Maria Kaparou , Zbigniew Rudzki , Hannah Giles , et al. Case Rep Hematology 2021 Jan 21;2021:8843063

3. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience
A Kanellopoulos, M Z Ahmed , B Kishore , R Lovell , C Horgan , S Paneesha , R Lloyd , B Salhan , H Giles , S Chauhan , I Venkatadasari, M Khakwani, V Murthy, E Xenou , H Dassanayake , S Srinath , M Kaparou , E Nikolousis, Case Reports  Br J Haematol  . 2020 Jul;190(2):e67-e70. doi: 10.1111/bjh.16856.

4. Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center 
Lloyd R, Nikolousis E, Kishore B, Lovell R, Shankara P, Zeid NA, Horgan C, Panteliadou AK, McIlroy G, Xenou E, Kaparou M, Holder K, Murthy V, Kanellopoulos A.Lloyd R, et al., Cell Transplant. 2020 Jan-Dec

5. First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation 
Horgan C, Kartsios C, Nikolousis E, Shankara P, Kishore B, Lovell R, Murthy V, Rudzki Z, Dyer S, Holtom P, Thompson G, Kaparou M, et al., Leuk Res Rep. 2020 Jun

6. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience 
Kanellopoulos A, Ahmed MZ, Kishore B, Lovell R, Horgan C, Paneesha S, Lloyd R, Salhan B, Giles H, Chauhan S, Venkatadasari I, Khakwani M, Murthy V, Xenou E, Dassanayake H, Srinath S, Kaparou M, et al., Br J Haematol. 2020 Jul;190(2):e67-e70

7. Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation
 McIlroy G, Nikolousis E, Abou-Zeid N, Shankara P, Kishore B, Kaparou M, Lovell R, Elmoamly S,  Davies D, Horgan C, Shenouda A, Kanellopoulos A., Leuk Lymphoma. 2019 Aug

8. Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience
Horgan C, Elmoamly S, McIlroy G, Davies D, Kaparou M, Giles H, et al., Leuk Lymphoma. 2019 May

9. Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia
Kanellopoulos A, Kaparou M, Xenou E, et al., Bone Marrow Transplant. 2018 Dec;53(12):1518-1521

10. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT- PACE in myeloma patients relapsing early after autologous transplant
Randall K, Kaparou M, Xenou E, Paneesha S, et al., Eur J Haematol. 2017 Jun 20. doi: 10.1111/ejh.12917. [Epub ahead of print]

11. Multiple cutaneous reticulohistiocytosis with T cell large granular lymphocyte clonopathy
Papadantonakis P, Kaparou M, Papadaki HA, Marinos L, Krasagakis K, Australas J Dermatol. 2017 Apr 4. doi: 10.1111/ajd.12608. [Epub ahead of print]

12. Myeloid Sarcoma: Presentation, Diagnosis and Treatment
L.M. Almond, M. Kaparou (Charalampaki), et al., Clinical Lymphoma, Myeloma and Leukemia, 2017;17( 5):263-7

13. Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features
Kaparou M, Choumerianou D, Perdikogianni C, Martimianaki G, Kalmanti M, Stiakaki E, Genet Mol Biol. 2013 Mar;36(1):7-11

14. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma
Tsirakis G, Pappa CA, Kaparou M, Boula A, Katsomitrou V, Xekalou A, Kyriakaki S, Alexandrakis MG., Tumour Biol. 2013 Apr;34(2):859-64

15. Prophylactic administration of fibrinogen concentrate in a pregnant woman with congenital hypofibrinogenemia and a positive obstetric history of severe bleeding in previous cesarean section
Kaparou M, Danilatou V, Lydaki E, Stathoudakis G, Bolonaki I, Nikoloudi I, Foundouli K., Blood Coagul Fibrinolysis. 2012 Sep;23(6):566-8

16. Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report
Tsirakis G, Kanellou P, Kaparou M, Passam A, Zampoulaki A, Stylianou K, Alexandrakis MG., ISRN Hematol. 2011;2011:404057

17. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients
Tsirakis G, Pappa CA, Kaparou M, Katsomitrou V, Hatzivasili A, et al., Eur J Histochem. 2011;55(3):e21

18. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment
Sfiridaki K, Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, et al., Mediators Inflamm. 2011;2011:867576

19. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma
Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, et al., Cytokine. 2011 Dec;56(3):616-20

20. CD19 Functional abnormalities of neutrophils in patients with myelodysplastic syndromes
H. Papadaki, M. Velegraki, A. Kozana, A. Zamboulaki, N. Kanellias, G. Gvazava, P. Kanellou, M. Kaparou, et al., Leukemia Research 33(1)

21. C027 The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome
H. Papadaki, I. Mavroudi, M. Psyllaki, K. Pyrovolaki, V. Papadaki, C. Kalpadakis, S Mastrodimou, M. Kaparou, et al., Leukemia Research, Volume 33, Supplement 1, May 2009, Pages S47-S48

Ώρες Λειτουργίας

Δευτέρα - Παρασκευή: 10:00 - 20:00
Σάββατο 10:00 - 14:00 (κατόπιν ραντεβού)

Κλείστε Ραντεβού

Γιατί Ξεχωρίζουμε

Εξειδίκευση και συνεχής ενημέρωση

like

Φροντίζουμε να ενημερωνόμαστε και να εφαρμόζουμε όλες τις σύγχρονες επιστημονικές εξελίξεις της ειδικότητάς μας ενώ διαθέτουμε, ήδη, μεγάλη εξειδίκευση και εμπειρία από σημαντικά ιατρικά κέντρα της Ελλάδας και του εξωτερικού.

Ασθενοκεντρική προσέγγιση

medical team

Κάθε ασθενής είναι για εμάς είναι μοναδικός, όπως και οι ανάγκες του, γι’ αυτό επιδιώκουμε σταθερά να δημιουργούμε δεσμούς εμπιστοσύνης, κατανόησης και αλληλοσεβασμού.

whyMidImage

Διαρκής υποστήριξη

love

Διαθέτουμε στους ασθενείς μας τον απαραίτητο χρόνο για να κατανοήσουν όλα όσα απαιτούνται σχετικά με τα στάδια της θεραπείας τους και επιδιώκουμε να απαντάμε σε κάθε προβληματισμό και ανησυχία τους.

Εξατομίκευση

quality control

Αξιολογούμε τις ανάγκες κάθε ασθενή και φροντίζουμε να παρέχουμε υψηλού επιπέδου ιατρικές υπηρεσίες, με γνήσιο ενδιαφέρον για κάθε άνθρωπο που μας εμπιστεύεται την πολύτιμη υγεία του.

Παθήσεις Αίματος

Είπαν για εμάς